AURIGA Study on Autologous Stem Cell Transplantation: Lenalidomide and Daratumumab in Myeloma Maintenance
Understanding AURIGA Study Findings
Autologous stem cell transplant (ASCT) continues to play a vital role in treating multiple myeloma. Recently, Ashraf Badros, MB, ChB, shared insights from the AURIGA study during the 21st annual International Myeloma Society's conference in Rio de Janeiro, Brazil. This study compares the efficacy of maintenance therapy using daratumumab combined with lenalidomide versus lenalidomide alone in patients newly diagnosed with multiple myeloma following ASCT.
Comparative Studies on Maintenance Therapy
According to Badros, the results of the AURIGA study emphasis the substantial benefits of incorporating daratumumab for post-ASCT maintenance therapy. When compared to previous studies, such as the CASSIOPEIA trial, the AURIGA study presents a clearer understanding of maintenance strategies in patient care. The research supports improved MRD (minimal residual disease) negativity and PFS (progression-free survival) outcomes.
Future Directions for Research
- Need for Additional Trials: There is a critical need for future trials to explore optimal duration of maintenance therapy.
- Approaches to Treatment: The integration of daratumumab has shown promising results, influencing treatment guidelines.
This transcript has been lightly edited for clarity. For further details, visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.